Latest news

• Lilly psoriasis drug beats J&J's Tremfya in head-to-head trial

  Shifting expectations in psoriasis outcomes. Eli Lilly’s Taltz (ixekizumab) has outperformed Johnson &Johnson’s Tremfya (guselkumab) in a head-to-head post-marketing trial in patients with moderate-to-severe ... The clean sweep of primary and major

• AbbVie’s Skyrizi gets rapid ‘yes’ from NICE

  It adds that indirect comparisons suggest Skyrizi is likely to provide similar health benefits compared with J&J’s IL-23 inhibitor Tremfya (guselkumab) (which gained NICE recommendation a year ago) ... of Tremfya – however confidential price

• Tremfya heads for filing in psoriatic arthritis

  Lilly's Talz sets pace with Humira head-to-head. J&J’s Tremfya has hit its primary endpoints in two phase 3 studies in psoriatic arthritis (PsA) putting it on ... J&J has unveiled top line data from the DISCOVER-1 and DISCOVER-2 phase 3 trials of

• Latecomer Lilly preps its IL-23 drug for Crohn’s disease

  Stelara has since been joined by J&J’s follow-up IL-23 inhibitor Tremfya (guselkumab), Sun Pharma’s Ilumya (tildrakizumab) and AbbVie/Boehringer Ingelheim’s Skyrizi (risankizumab), which are all ... Tremfya also has data suggesting it works in

• Novartis claims first place for psoriasis drug Cosentyx in China

  makes it the market ahead of other interleukin-targeting rivals including Johnson &Johnson’s Tremfya (guselkumab), which are also en route to market. ... J&J is running a head-to-head trial of Tremfya versus Cosentyx in psoriasis to try to ramp up that